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Available online 10 March 2016Background: Cardiovascular system involvement in patients with Plasmodium vivaxmalaria has been poorly ad-
dressed. The aim of this study was to evaluate cardiac structures and function, and serum markers of cardiovas-
cular injury in patients with the non-severe form of vivax malaria in Manaus, Amazonas State, Brazil.
Methods and results:Weprospectively evaluated 26 patients with vivaxmalaria in an outpatient referral hospital
and compared results with a control group of 25 gender- and age-matched healthy individuals. Patients
underwent clinical evaluation, laboratory tests, and transthoracic echocardiography at ﬁrst evaluation (day
zero, D0) and seven days (D7) after malaria diagnosis. At D0 echocardiography showed higher left ventricular
(LV) systolic diameter (28.8 ± 2.82 vs 30.9 ± 4.03 mm; p = 0.037) and LV diastolic volume (82.4 ± 12.3 vs
93.8 ± 25.9 ml; p = 0.05), and lower LV ejection fraction (Teicholz method: 73.2 ± 6.59 vs 68.4 ± 4.87%;
p = 0.004) in patients compared to controls. Right ventricle (RV) fractional area change (54.7 ± 5.11 vs
50.5 ± 6.71%; p = 0.014) was lower, and RV myocardial performance index (0.21 ± 0.07 vs 0.33 ± 0.19; p =
0.007), and pulmonary vascular resistance (1.13 ± 0.25 vs 1.32 ± 0.26 Woods unit; p = 0.012) were higher in
patients than controls. Patients presented higher serum levels of unconjugated bilirubin (0.24 ± 0.15 vs
1.30 ± 0.89 mg/dL; p b 0.001), soluble vascular cell adhesion molecule–1 (sVCAM-1; 453 ± 143 vs 1983 ±
880 ng/mL; p b 0.001), N-terminal prohormone brain natriuretic peptide (0.59 ± 0.86 vs 1.08 ± 0.81 pg/mL;
p = 0.045), and troponin T (861 ± 338 vs 1037 ± 264 pg/mL; p = 0.045), and lower levels of plasma nitrite
(13.42 ± 8.15 vs 8.98 ± 3.97 μM; p = 0.016) than controls. Most alterations had reversed by D7.
Conclusion: Patients with non-severe Plasmodium vivax malaria present subclinical reversible cardiovascular
changes.
© 2016 TheAuthors. Published by Elsevier Ireland Ltd. This is an openaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Malaria, a common parasitic disease affecting humans, is one of
the most important public health issues in developing countries [1].
In 2013, there were 104 countries with endemic malaria, withability and freedom from bias of
r. Heitor Vieira Dourado”, Av.
, Brazil.
r-Filho).
land Ltd. This is an open access articlapproximately 198 million people affected and an estimated 584
thousand deaths [1].
Malaria pathophysiology has been extensively studied. However,
since the ﬁrst reports by Laveran [2] in 1884 describing myocardial
and coronary changes in patients dying from malaria, few studies have
carefully evaluated the cardiovascular system in malaria. These clinical
and experimental studies have suggested that acute infection is accom-
panied by parasite sequestration and obstruction in microvascular cor-
onary and myocardial injury caused by parasite released proteins as
well as inﬂammatory cytokines and anemia [3–8]. More recently,
falciparum malaria patients were shown to present endotheliale under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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increased pulmonary artery pressure [4,9].
All studies on cardiovascular involvement in malaria have been per-
formed on Plasmodium falciparummalaria, which is related to the most
severe form of the disease affecting several organs and systems [10]. Of
the various Plasmodium species, Plasmodium vivaxwas previously con-
sidered to cause a benign non-fatal infection. However, in the last de-
cade several reports have linked P. vivax to systemic complications
involving the central nervous system, renal and respiratory failure, ab-
normal bleeding, anemia, and jaundice [11–16]. To the best of our
knowledge, there are no studies analyzing the cardiovascular system
during P. vivax malaria. In this study, we evaluated cardiac structures
and function by Doppler-echocardiogram and plasmatic markers of
cardiovascular injury in patients with the non-severe form of P. vivax
malaria in Manaus, Amazonas State, Brazil.
2. Materials and methods
2.1. Study subjects
In a case–control study,we prospectively evaluated outpatientswith
P. vivaxmalaria attending the Dr. Heitor Vieira Dourado Tropical Medi-
cine Foundation (FMT-HVD), in Manaus, Brazil, between December
2012 and March 2013. The FMT-HVD is a tertiary care center for infec-
tious diseases,where patients can either seek attention directly or be re-
ferred for specialized care in neighboring municipalities. The study
protocol conforms to the ethical guidelines of the 1975 Declaration of
Helsinki as reﬂected in a priori approval by FMT-HVD Research Ethics
Committee. All individuals signed the informed consent.
Patients aged 18–60 years were eligible to participate if they had no
known illness and were diagnosed with P. vivax malaria to be treated
out of hospital (P. vivax group, n = 26). Age and gender-matched indi-
viduals testing negative for malaria comprised the Control group (n =
25). The controls had similar economic conditions and lived in the
same neighborhood as the patients. Exclusion criteria included electro-
cardiographic changes suggesting regional abnormalities, heart valve
disease, and previously diagnosed severe diseases such as stage C
heart failure, renal or liver insufﬁciency, cancer, pregnancy, malaria
other than P. vivax, or severe malaria needing in-hospital treatment ac-
cording to the World Health Organization [1]. All patients had positive
thick blood smear and real-timeqPCR assay for P. vivaxmalaria. Controls
tested negative in both tests. Patients were treated with a combination
of chloroquine and primaquine or a combination of artesunate and
amodiaquine.
All individualswere subjected to the following:medical history eval-
uation, physical examination, 12-lead resting electrocardiogram, trans-
thoracic Doppler-echocardiogram, and Laboratory investigation. In
patients, clinical and laboratory evaluation was performed before treat-
ment (day zero, D0) and seven days after starting treatment (day seven,
D7). Medical history and physical examination were performed to
assess general health and to clinically exclude diseases or conditions
described in the exclusion criteria. Blood pressure was measured
by the auscultatory technique with a conventional mercury
sphygmomanometer.
2.2. Echocardiographic evaluation
A standard echocardiography system (General Electric Medical
Systems, Vivid 3) was used to measure cardiac structures as previously
described and following American Society of Echocardiography recom-
mendations [17–20]. All echocardiograms were performed by the same
examiner (JMBBF). With individuals positioned in left lateral decubitus
position andmonitoredwith an electrocardiographic lead, the following
echocardiographic cuts were performed: short parasternal axis to mea-
sure ventricles, aorta and left atrium; apical 2, 4 and 5 chambers to eval-
uate ventricular cavities and systolic and diastolic function. The averageof three measurements was calculated for each variable. The following
left ventricular (LV) structures were measured by two-dimensional
guided M-mode images: diastolic and systolic diameters (LVDD and
LVSD, respectively), and diastolic and systolic volume (LVDV and
LVSV, respectively). LV systolic function was evaluated by measuring
ejection fraction according to the Teicholz index, endocardial fractional
shortening, and myocardial performance index (Tei index) [21]. Right
ventricle (RV) was structurally evaluated by measuring diastolic and
systolic areas. RV systolic function was evaluated by fractional area
change (FAC), and Tei index. Pulmonary vascular resistance (PVR) was
estimated by Doppler echocardiography [22] according to the formula:
PVR = tricuspid regurgitation peak velocity/right ventricular outﬂow
tract velocity time integral) X 10+0.16. Pulmonary artery systolic pres-
sure (PASP) was estimated by Doppler echocardiography using the
modiﬁed Bernoulli equation 22: PASP = 4 X (tricuspid regurgitation
peak velocity) [2] + right atrial pressure. Right atrial pressure was esti-
mated from inferior vena cava diameter [22].
2.3. Laboratorial analysis
Venous blood samples were obtained after a 12–15 h overnight fast
in EDTA-coated tubes. Plasmawas frozen at−80 °C in tubes containing
5 μL/mL antioxidant butyl hydroxytoluene (BHT, 20 μM), proteases in-
hibitor (aprotinin, 2 mg/mL), phenylmethylsulphonyl ﬂuoride (PMSF,
1 mM), and benzamidine (2 mM). Nitrite plasma concentration was
quantiﬁed by colorimetry using a commercially available nitric oxide
assay kit (Cayman, Chemical Company, AnnArbor, Michigan, USA). Con-
centrations of N-terminal prohormone brain natriuretic peptide (NT-
proBNP) and troponin T were measured by ELISA using commercially
available kits (USCN Life Science Inc., Houston, Texas, USA). Soluble vas-
cular cell adhesionmolecule (sVCAM)-1 concentrationwas analyzed by
immunoassay using a commercially kit (R&DSystems, Inc.,Minneapolis,
Minnesota, USA). All kits used in this study are available for laboratory
research use only, not for human diagnostics.
Subjects were tested for malaria by thick blood smear. Parasite den-
sity was calculated by the arithmetic mean of two concordant readings;
the white blood cell count was obtained from total blood count analysis
as previously described [23]. In case of discordance (species-speciﬁc, or
in the density quantiﬁcation whenever a discrepancy was higher than
10%), a third reading was performed by a senior investigator (WMM).
Real-time qPCR was performed as previously described [24] to conﬁrm
P. vivaxmalaria.
2.4. Statistical analysis
Variables are presented as mean and standard deviation or median
and minimum and maximum values. Comparisons between periods
were performed by Student's t test for dependent data and comparisons
between groups were performed by unpaired Student's t test. Categor-
ical parameters were compared by Fisher's exact test. The association
between variables was assessed with Pearson's correlation coefﬁcient.
The level of signiﬁcance was 5%. Statistical analyses were performed
using IBM SPSS Statistics software Version 21.
3. Results
Baseline characteristics for controls and patients at day zero (D0) are
presented in Table 1. Heart rate, althoughwithin the normal range, was
higher in P. vivax group than Controls.
The P. vivax group had a mean peripheral parasitemia of 2844 ±
3286 parasites/mm3, ranging from 87 to 11,806 parasites/mm3. Labora-
tory data are shown in Table 2. P. vivaxD0had increased plasma concen-
trations of unconjugated bilirubin, troponin T, NT-proBNP, and sVCAM-
1 and decreased platelet count and nitrite levels compared to Controls.
At D7, unconjugated bilirubin, troponin T, NT-proBNP, and sVCAM-1
were lower, and platelet count and nitrite levels higher than D0. Sixty
Table 1
Baseline characteristics at day zero (D0).
Control (n = 25) P. vivax (n = 26) P-value*
Age, years 44.5 ± 8.43 41.7 ± 13.7 0.37
Female, % 44.0 30.8 0.39*
Height, m 1.67 ± 0.07 1.67 ± 0.08 0.99
Body weight, kg 79.3 ± 15.0 79.0 ± 13.9 0.87
BMI 28.3 ± 4.54 28.2 ± 5.07 0.93
Systolic blood pressure, mm Hg 121 ± 11.6 121 ± 12.2 0.98
Diastolic blood pressure, mm Hg 79 ± 8.6 78 ± 8.1 0.69
Heart rate, bpm 66 ± 7.6 76 ± 13.2 0.02
Data are mean and standard deviation or frequency. BMI: body-mass index (weight in
kilograms divided by the square of height in meters); and bpm: beats/min. Unpaired
Student's t test or Fisher's exact test (*).
Table 3
Left ventricular echocardiographic data.
Control
(n = 25)
P. vivax D0
(n = 26)
P. vivax D7
(n = 26)
P-Value
P. vivax
D0 X Control
P. vivax
D7 X D0
LVSD, mm 28.8 ± 2.82 30.9 ± 4.03 30.1 ± 3.04 0.037 0.46
LVDV, mL 82.4 ± 12.3 93.8 ± 25.9 91.1 ± 19.8 0.050 0.67
EF, % 73.2 ± 6.59 68.4 ± 4.87 70.3 ± 4.78 0.004 0.15
EFS, % 42.8 ± 5.81 38.4 ± 3.28 40.2 ± 4.07 0.003 0.11
Tei index 0.31 ± 0.64 0.36 ± 0.12 0.35 ± 0.10 0.88 0.70
Data aremean and standard deviation. D0: day zero; D7: day seven; LVSD: left ventricular
(LV) systolic diameter; LVDV: LV diastolic volume; EF: ejection fraction; EFS: LV endocar-
dial fractional shortening. Unpaired Student's t test P. vivax D0 vs Control; and paired
Student's t test P. vivax D7 vs P. vivax D0.
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D0; no patient presented clinical bleeding or severe thrombocytopenia
(b50,000 platelets/μL).
LV echocardiographic data are shown in Table 3. At D0, the P. vivax
group presented higher LV systolic diameter and lower ejection fraction
and endocardial fractional shortening than Controls. LV variables did
not signiﬁcantly differed between D7 and D0 in the P. vivax group. RV
data are shown in Table 4. At D0, the P. vivax group had higher RV dia-
stolic and systolic area, Tei index, and pulmonary vascular resistance,
and lower fractional area change than Controls. In P. vivax patients, frac-
tional area change was higher and pulmonary vascular resistance lower
in D7 thanD0. At D0, NT-proBNP levels positively correlatedwith RV di-
astolic (r= 0.409; P= 0.038) and systolic (r= 0.435; P= 0.026) areas
andwith Tei index (r= 0.493; P= 0.01) and pulmonary vascular resis-
tance positively correlated with RV Tei index (r = 0.646; P b 0.001) in
malaria patients.
4. Discussion
In this study we evaluated cardiac structures and function by Dopp-
ler echocardiography and systemic markers of cardiovascular injury in
patients with the non-severe form of P. vivaxmalaria at the beginning
of infection and seven days later.
Malaria was diagnosed by examining thick blood smears and P. vivax
malariawas conﬁrmed by real-time qPCR assay. As jaundice is a diagno-
sis criteria for severe malaria, no icteric patient was included in this
study. Nonetheless, mean unconjugated bilirubin values were higher
atD0 in P. vivax than Controls suggesting a lowdegree of hemolysis.Ma-
laria patients had a slight decrease in platelet count at D0, which is com-
monly observed in vivax malaria and may be related to platelet
phagocytosis [25,26]. Platelet counting often normalizes after treatment
[25].
As markers of myocardial injury, we evaluated plasma concentra-
tions of troponin T and NT-proBNP, which were higher at D0 in
P. vivax than Controls and D7 P. vivax. The troponin T levels in our ma-
laria patients suggest a slight degree of myocardial injury. NT-proBNP
concentration is often used for heart failure diagnosis and prognosis.
More recently, it has also been considered a good biomarker for pulmo-
nary arterial hypertension and right ventricular dysfunction [27]. TheTable 2
Laboratorial data.
Control (n = 25) P. vivax D0 (n = 26)
UCB, mg/dL 0.24 ± 0.15 1.32 ± 0.89
Platelets, X 1000 cells/mm3 281 ± 64 145 ± 60
Troponin T, pg/mL 861 ± 338 1037 ± 264
NT-proBNP, pg/mL 0.59 ± 0.86 1.08 ± 0.81
sVCAM-1, ng/mL 453 ± 143 1983 ± 880
Nitrite, μM 13.4 ± 8.15 8.98 ± 3.97
Data are mean and standard deviation. D0: day zero; D7: day seven; UCB: unconjugated bilirub
cular cell adhesion molecule; unpaired Student's t test P. vivax D0 vs Control; and paired Studehigher NT-proBNP levels in D0 P. vivax than Controls is probably related
to acute dilation of the left and right ventricles.
Soluble vascular cell adhesionmolecule-1 contributes to endothelial
activation and dysfunction, which are involved in the pathogenesis of
several infectious diseases [28]. In hemolytic conditions such as sickle-
cell anemia andmalaria, sVCAM-1 levels are usually increased [28]. It fa-
cilitates adhesion of infected and non-infected blood red cells to endo-
thelium, resulting in ﬁbrin and platelet deposition, and microvascular
sequestration and obstruction [29–31]. Expression of sVCAM-1 may be
induced by proinﬂammatory cytokines and nitric oxide depletion [4,
32]. Nitric oxide depletion also impairs vasodilation [33]. In this study,
plasma concentration of sVCAM-1 was higher and nitrite levels lower
in D0 P. vivax than Controls. Similar results were found in children
with falciparum malaria [4] and endothelial activation was previously
observed in uncomplicated vivax malaria [34]. Nitrite is considered as
a physiological storage pool of nitric oxide that can be reduced to bioac-
tive nitric oxide in hypoxic conditions to mediate physiological re-
sponses in blood and tissue [35]. D7 sVCAM-1 was lower and nitrite
higher than at D0 in malaria patients.
In this study, the P. vivax group presented slight left ventricular dila-
tion with reduced systolic function compared to Controls at D0. Left
ventricular echocardiographic parameters did not signiﬁcantly differ
betweenD7 andD0 in the P. vivax group. At D0, P. vivax group presented
right ventricular dilation, characterized by increased diastolic and sys-
tolic areas, and right ventricular dysfunction, characterized by reduced
fractional area change and increased Tei index, with increased pulmo-
nary vascular resistance. Fractional area change has been used to evalu-
ate right ventricular systolic function, presenting a good correlation
with ejection fraction estimated by cardiacmagnetic resonance imaging
[36]. Furthermore, in this study, right ventricular diastolic and systolic
area and Tei index positively correlated with NT-proBNP levels. Alter-
ations in right ventricle function and pulmonary vascular resistance
were reversible after treatment, as suggested by the higher fractional
area change and the lower pulmonary vascular resistance at D7 com-
pared to D0. Right ventricular dilation may be the ﬁrst indicator of an
acute increase in pulmonary vascular resistance; and increased pulmo-
nary vascular resistance can be related to vasoconstriction, inﬂamma-
tion, and obstruction of pulmonary arteries in malaria [22,37].P. vivax D7 (n = 26)
P-Value
P. vivax D0 X Control P. vivax D7 X D0
0.33 ± 0.15 b0.001 b0.001
341 ± 77 b0.001 b0.001
784 ± 249 0.045 b0.001
0.63 ± 0.51 0.045 0.027
849 ± 467 b0.001 b0.001
12.3 ± 5.30 0.016 0.014
in; NT-proBNP: N-terminal prohormone brain natriuretic peptide; sVCAM-1: soluble vas-
nt's t test P. vivax D7 vs P. vivax D0.
Table 4
Right ventricular echocardiographic data.
Control
(n = 25)
P. vivax D0
(n = 26)
P. vivax D7
(n = 26)
P-Value
P. vivax
D0 X Control
P. vivax
D7 X D0
DA, cm2 13.0 ± 3.19 15.3 ± 2.96 15.1 ± 2.55 0.009 0.762
SA, cm2 6.41 ± 1.27 7.45 ± 1.46 6.96 ± 1.41 0.009 0.220
FAC, % 54.7 ± 5.11 50.5 ± 6.71 55.7 ± 6.90 0.014 0.007
Tei index 0.21 ± 0.07 0.33 ± 0.19 0.27 ± 0.10 0.007 0.170
PVR, Wood
units
1.13 ± 0.25 1.32 ± 0.26 1.17 ± 0.19 0.012 0.031
PASP, mm Hg 19.2 ± 2.95 19.7 ± 3.05 19.8 ± 4.19 0.576 0.922
Data aremean and standard deviation. D0: day zero; D7: day seven;DA: diastolic area; SA:
systolic area; FAC: fractional area change; PVR: pulmonary vascular resistance; PASP:
pulmonary artery systolic pressure. Unpaired Student's t test P. vivax D0 vs Control; and
paired Student's t test P. vivax D7 vs P. vivax D0.
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diac structures and function in patients with vivax malaria. Our data
suggest that outpatientswith P. vivaxmalaria present subclinical cardio-
vascular changes and allow us to hypothesize that events previously de-
scribed in severe falciparummalaria [4,9,38,39] also occur in non-severe
vivax malaria. Products from low grade hemolysis of parasitized red
blood cells induce a reduction in plasmanitrite, which is relatedwith ni-
tric oxide bioavailability. Increased expression of cellular adhesionmol-
ecules such as sVCAM-1 facilitates adherence to vascular endothelium
and destruction of infected reticulocytes and non-infected erythrocytes.
Nitric oxide depletion decreases vasodilation therefore increasing pul-
monary vascular resistance and impairing right ventricular function.
Additionally, left ventricular dilation and dysfunction may result from
infection, depleted nitric oxide-induced increase in afterload, and/or
microvascular obstruction. The increase in NT-proBNP, suggesting dila-
tion of cardiac chambers, and troponin T, suggestingmyocyte injury, re-
inforces myocardial injury during P. vivaxmalaria. Most alterations are
reversible seven days after treatment.
5. Limitations
This study evaluated a small sized sample of outpatients with vivax
malaria, which allowed us to raise a hypothesis on the pathophysiolog-
ical events involved in cardiovascular changes. Therefore, additional
studies are needed to evaluate a larger sample of both P. vivaxmalaria
in- and out-patients in order to conﬁrm our results and to extend the
understanding of vivax malaria to patients with the severe form of the
disease.
In conclusion, patients with non-severe P. vivax malaria present
subclinical cardiovascular changes.
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